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Background: Patients with type 2 diabetes have 2–4 times greater risk for cardiovascular morbidity and mortality
than those without, and this is even further aggravated if they also suffer from hypertension. Unfortunately, less
than one third of hypertensive diabetic patients meet blood pressure targets, and more than half fail to achieve
target HbA1c values. Thus, appropriate blood pressure and glucose control are of utmost importance. Since
treatment sometimes fails in clinical practice while clinical trials generally suggest good efficacy, data from daily
clinical practice, especially with regard to the use of newly developed anti-diabetic and anti-hypertensive
compounds in unselected patient populations, are essential. The DIALOGUE registry aims to close this important
gap by evaluating different treatment approaches in hypertensive type 2 diabetic patients with respect to their
effectiveness and tolerability and their impact on outcomes. In addition, DIALOGUE is the first registry to determine
treatment success based on the new individualized treatment targets recommended by the ADA and the EASD.
Methods: DIALOGUE is a prospective observational German multicentre registry and will enrol 10,000 patients with
both diabetes and hypertension in up to 700 sites. After a baseline visit, further documentations are scheduled at 6,
12 and 24 months. There are two co-primary objectives referring to the most recent guidelines for the treatment of
diabetes and hypertension: 1) individual HbA1c goal achievement with respect to anti-diabetic pharmacotherapy
and 2) individual blood pressure goal achievement with different antihypertensive treatments. Among the
secondary objectives the rate of major cardio-vascular and cerebro-vascular events (MACCE) and the rate of
hospitalizations are the most important.
Conclusion: The registry will be able to gain insights into the reasons for the obvious gap between the
demonstrated efficacy and safety of anti-diabetic and anti-hypertensive drugs in clinical trials and their real world
balance of effectiveness and safety.
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There is an increasing prevalence of type-2 diabetes,
which is attributable to a growing population, an in-
crease in life expectancy, increased diagnostic efforts,
and a reduced diabetes attributable risk due to recent
advances in diabetes treatment [1]. Hypertension is the
most frequent (90%) among the co-morbid disease con-
ditions [2] and further increases the risk for disease and
treatment related complications [3]. The combination of
both hypertension and diabetes accelerates the progres-
sion of diabetes related complications such as diabetic
nephropathy, retinopathy, left ventricular hypertrophy,
and diastolic heart failure and doubles the risk of stroke,
CV and all-cause mortality as compared to non-diabetic
patients with hypertension. Risk prediction in this popu-
lation is however not easy making the adaption of avail-
able risk prediction tools necessary, partly because risks
have gone down in recent years [4].Glucose and blood pressure control
A number of studies have shown improved glycaemic
control to be able to delay the onset and also to halt the
progression of micro-vascular complications such as dia-
betic retinopathy and nephropathy. This has also been
shown for neuropathic secondary disorders [5,6]. For
macro-vascular complications, however, the picture to
date is less straightforward. There is doubt as to whether
the benefit of tight glycaemic control on macro-vascular
events is as great as the one effected by blood pressure
and lipid control. A recent meta-analysis of five large
trials [7] found a significant reduction in event rates for
non-fatal myocardial infarction and also for CAD, but
all-cause mortality and stroke rates were not similarly
affected.
An exploratory analysis of the United Kingdom Pro-
spective Diabetes Study (UKPDS) data showed that the
risk of both micro- and macro-vascular complications of
type 2 diabetes (T2D) was strongly associated with the
mean systolic blood pressure and that blood pressure
lowering by 10 mmHg led to a 15% reduction in the risk
for death related to diabetes [8].
In the Steno-2 study, intensified therapy of the modifi-
able risk factors in patients with T2D and microalbumi-
nuria was compared to standard treatment. In addition
to lifestyle changes and diet modifications, all patients in
this group received ACE-inhibitors (ACEI) or angioten-
sin receptor blockers (ARB) irrespective of baseline BP
values and a vitamin-mineral supplement. The target
limits for HbA1c, fasting cholesterol and triglycerides
and blood pressure were much stricter than in the con-
trol group. This multi-factorial approach led to signifi-
cant reductions in both micro- and macro-vascular
event rates [9,10].Thus, in diabetic patients with hypertension, appropri-
ate blood pressure control as well as glucose control is
important. Current guidelines [11,12] recommend a
multi-factorial approach with simultaneous targeting of
blood pressure and glucose levels. Unfortunately, less
than one third of the hypertensive diabetics meet their
blood pressure targets and less than half of them their
HbA1c target.
Pharmacotherapy
During recent years new medications and fixed dose
combinations have been developed for the treatment of
T2D and hypertension. For achieving glycaemic control,
a number of oral therapeutic options are available, using
different approaches. There are agents that increase in-
sulin secretion, such that improve insulin action and also
substances delaying carbohydrate absorption. Unfortu-
nately, most of them – with the exception of metformin
– are associated with weight gain. Hypoglycaemia and in
some cases gastrointestinal side effects and oedema are
other possible disadvantages. Another issue is the failure
to achieve adequate control of postprandial blood glu-
cose and also long term glycaemic control [13]. In recent
years, incretin-based treatments like DPP-4 inhibitors
(Vildagliptin, Sitagliptin, Saxagliptin, Linagliptin) have
been shown to be a potent strategy and are increasingly
used in fixed dose combinations (e.g. with metformin)
[14-18]. As these drugs display different properties, e.g.
pharmacokinetics, they influence the glycaemic profile in
T2D – patients in different ways. This may be measure
by the Mean Amplitude of Glycaemic Excursions
(MAGE) and Rizzo confirmed that MAGE reduction
was associated with reduction of oxidative stress and
markers of systemic inflammation in T2D patients [19].
Since glucose variations over time, linked to circadian
fluctuations of glucose levels, are associated with an acti-
vation of oxidative stress, the main mechanisms that
lead to chronic diabetic complications [20], these data
suggest that any therapy should aim not only to reduce
HbA1c but also to flatten acute glucose fluctuations over
time to positively influence the outcome of T2D
patients.
To achieve adequate blood pressure control, an even
larger number of therapy options exist. As diabetic
patients frequently also have impaired renal function
associated with microalbuminuria, substances affecting
the renin-angiotensin system, which are known to dis-
play renal benefits independent of blood pressure reduc-
tion, appear to be particularly beneficial [21-23]. ACEI
and ARB are available in several fixed dose combinations
with calcium channel blockers like amlodipine and/or
diuretics like hydrochlorothiazide. Interestingly, the use
of fixed dose combinations has been shown to signifi-
cantly improve compliance by reducing pill burden
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achievement and lower hospitalisation rates.
Guideline compliance in daily clinical practice
Treatment recommendations by current guidelines are
mainly based on evidence from randomised controlled
trials. However, these trials reflect only selected patient
populations defined by detailed in- and exclusion criteria
of these trials. Patients in daily practice are usually older
and suffer from more co-morbidities as compared to
those in clinical trials [26,27]. Available data suggest sub-
optimal treatment target achievement with respect to
glucose, blood pressure and lipid control [28-31]. While
there are quite some data on patient characteristics,
current treatments and outcome of diabetics with hyper-
tension in clinical practice, there are much less especially
with respect to the use of newly developed and approved
anti-hypertensive and anti-diabetic compounds and phy-
sicians approach towards its management [32]. Add-
itionally, it is quite unclear if and how the different
combinations of anti-diabetic and anti-hypertensive
medications contribute to the achievement and preser-
vation of target blood glucose and blood pressure values
in individual patients.
Aim
The purpose of the registry is to evaluate various therapy
regimes of anti-diabetic (including incretin-based and
exclusively non-incretin-based therapies) and anti-
hypertensive treatments (including RAAS-inhibitors and
exclusively non-RAAS-inhibitors) as well as their combi-
nations, patient reported outcomes and treatment suc-
cess in hypertensive T2D patients. It is the first
prospective registry to determine treatment success
based on the new individualized treatment targets of the
ADA and the EASD [33].
Methods/Design
DIALOGUE is a prospective observational national mul-
ticentre registry with a follow-up of 24 months and will
enrol 10,000 patients with both T2D and hypertension
from up to 700 sites in Germany. Data are recorded at
baseline and will be prospectively documented during
follow up visits at 6, 12 and 24 months.
This registry is conducted in accordance with the eth-
ical principles that have their origin in the Declaration
of Helsinki and adhere to the principles of Good Epi-
demiology Practice (GEP), and applicable regulatory
requirements. The protocol of this registry was approved
by the ethics committee of the Ruhr University Bochum,
Germany. Patients that being enrolled into this registry
will provide written informed consent. DIALOGUE has
further been registered in the database of the Verband
forschender Arzneimittelhersteller (VFA).Primary objective
The two co-primary objectives are: 1) documentation of
individual HbA1c goal achievement with respect to anti-
diabetic pharmacotherapy and 2) documentation of indi-
vidual blood pressure goal achievement with different
anti-hypertensive treatments.
Secondary objective
Secondary objectives are (1) to document major cardio-
vascular and cerebro-vascular events (MACCE) during 2
year follow-up; (2) to document hospitalizations during
2 year follow-up; (3) to assess the proportion of patients
reaching blood glucose target values without experien-
cing the following adverse effects: peripheral oedema or
proven hypoglycaemic events or discontinuation due to
gastrointestinal events or significant weight gain (>5%);
(4) to describe patient characteristics in patients with
diabetes mellitus and hypertension in clinical practice in
the overall registry population; (5) to document anti-
diabetic and anti-hypertensive therapy and its impact on
treatment target achievements in diverse subject popula-
tions, which have to be pre-specified by the scientific
committee (e.g. females versus males, age </>75y,
patients on insulin versus patients not on insulin, etc.);
(6) to verify the applicability of and the adherence to the
current guidelines for the treatment of diabetes and
hypertension in clinical practice; (7) to document utilisa-
tion patterns of drugs used for the treatment of diabetes
as well as hypertension in clinical practice; (8) To evalu-
ate adverse cardio-vascular events as well as diabetes-
related micro-vascular and macro-vascular events; (9) to
evaluate the glycaemic profiles of the participants with
regards to differences in anti-diabetic treatment patterns;
(10) to evaluate the blood pressure profiles; (11) To
evaluate co-morbid disease conditions; (12) to evaluate
the change in BMI over the course of the study; (13) to
evaluate the proportion of patients with hypoglycaemic
events over the course of the follow-up; (14) to evaluate
cardio-vascular risk by using validated cardio-vascular
risk scores such as the EURO Score; (15) to evaluate
health status (EQ-5D); (16) to determine costs associated
with the treatment and disease related complications;
(17) to document treatment persistence over time,
change in treatments / dosing during a follow-up of two
years (optional up to 4 years of follow-up); (18) to docu-
ment patient reported outcome (PRO).
Selection of sites
The registry will be performed in primary care and dia-
betes centres in Germany, with a planned participation
of up to 700 sites. Centres will be selected from a data-
base maintained at the Institut für Herzinfarktforschung
to be representative for the ambulatory treatment of dia-
betes and hypertension in Germany. For this purpose, a
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including diabetologists and primary care physicians will
be built. The sampling strategy will thus provide a repre-
sentative dataset for the description of oral anti-diabetic
treatment patterns in Germany.
Selection of patients
Inclusion criteria are as follows: 1) Age: ≥18 years 2)
Diagnosed type 2 diabetes mellitus and manifest hyper-
tension (comorbidity) 3) Antidiabetic therapy presently
on oral mono- or dual combination therapy (no insulin,
no GLP-1 analogue) 4) The treating physician considers
blood glucose lowering medication to be not adequate
and/or not safe/tolerable 5) The physician adds another
oral drug / switches drug treatment to achieve glycaemic
control 6) Written informed consent for participation
obtained from the subject.
Patients will not be eligible for inclusion if any of the
following exclusion criteria apply: 1.) Current participa-
tion in any randomised controlled trial. 2) Patients not
under regular supervision of the treating physician for
the duration of the study 3) Use of GLP-1-analogues or
insulin before enrolment 4) Patients treated with aliski-
ren in a dual renin angiotensin aldosterone (RAAS)
blockade 5) Pregnancy 6) Diabetes secondary to malnu-
trition, infection or surgery 7) Maturity onset diabetes of
the young 8) Known cancer.
Patients will be enrolled according to a pre-specified
ratio based on their treatment, which is not pre-
determined by the study protocol but based on the phy-
sician’s decision (Figure 1). “Incretin-based treatment” is
defined as either a DPP-4 inhibitor or a GLP-1 analogue.
“Non-incretin-based treatment” is defined as any of the
following: metformin, sulfonylureas, acarbose, insulin,
alpha-glucosidase inhibitors, and/or SGLT2-inhibitors.
As the clinical profile of vildagliptin appears to differ
from that of other DPP-4 inhibitors, the “incretin-based
treatment” group will be split into those with or without
vildagliptin.Consecutive patients with d









Figure 1 Sample size and segmentation into strata of different antidi
with oral mono or dual combination therapy and are distributed into the f
and GLP-1 analogues. Non-incretin-based therapies include metformin, sulf
inhibitors.Recruitment plan
Patient enrolment has started in July 2012. It is esti-
mated that the first visit of the last patient enrolled will
take place in early 2013, the last visit of the last patient
is planned for early 2015. The Clinical Study Report will
then be published in April of the following year. Figure 2
gives an overview of the timelines and the points when
interim analyses to be performed.
Documented variables
Table 1 gives an overview of the variables to be docu-
mented. Source documentation and data accuracy will
be verified by site visits in randomly selected 2% of the
sites.
Quality assurance
There are three strategies for data quality checks: valida-
tions that occur at the time of data entry (i.e., “front-end”),
a second, more sophisticated quality control program that
runs as a prelude to the creation of the analysis data set
and on-site data monitoring.
Front-end data checks are advantageous because mis-
takes are caught and corrected at the time of entry – a
system that is efficient for data collectors. Certain data
elements can be required, while other variables may
allow for missing values. Additionally, parameters will be
defined to allow entry of only those records that meet
inclusion criteria.
Prior to the creation of the analytic dataset, more ex-
tensive quality control processes are performed. These
checks, programmed in SAS, include parent–child edits,
consistency edits, and data transformations that will fa-
cilitate analyses.
Source documentation and data accuracy will be veri-
fied by site visits in randomly selected 2% of the sites.
Statistical methods
All variables collected in the eCRF as well as the data
obtained from the quality of life assessments and alliabetes and hypertension 
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Figure 2 Estimated enrolment and planned interim-analyses as well as follow-up periods. Legend: IA, Interim Analysis, PO, Primary
Objective; FU, Follow-up.
Gitt et al. Cardiovascular Diabetology 2012, 11:148 Page 5 of 8
http://www.cardiab.com/content/11/1/148derived parameters will be used in the statistical analysis.
Binary, categorical, and ordinal parameters will be sum-
marised by means of absolute and percentage numbers
within the various categories (including ‘missing data’ as
valid category at baseline). Numerical data will be sum-
marised by means of standard statistics (i.e. number of
available data, number of missing data, mean, standard
deviation, minimum, median, maximum, lower and
upper quartile). In addition, adequate graphs (e.g. bar
charts, box-whisker plots) may be presented to summar-
ise the results for some parameters. Time-to-event vari-
ables will be analysed via a Cox proportional hazard
regression model presenting hazard ratios and the cor-
responding 95% confidence intervals. In addition
Kaplan-Meier curves will be presented for these vari-
ables. Two-sided 95%-CI will be presented for important
parameters, but should be interpreted in an exploratory
descriptive way. Further multivariable analyses will be
performed according to the statistical analysis plan
(SAP). Formal statistical tests will not be performed
within the statistical analysis. A report including descrip-
tive statistics of all documented parameters will beTable 1 Overview of documented parameters
Visit Baseline
Sociodemographics 1 x
Physical examination 2 x
Cardiovascular concomitant diseases 3 x
Diabetes associated diseases 4 x
Available laboratory values5 x
Antidiabetic medication6 x
Additional current medication x
Hypoglycaemic events8 x
QoL (EuroQoL-5D) x
Patient reported outcomes (PRO) x
Legend: 1) age, gender, insurance status, DMP participation, education, employmen
consumption, physical activity 3) coronary heart disease, previous myocardial infarc
peripheral artery occlusive disease 4) dyslipidemia, amputation, autonomous neuro
blindness, dialysis other 5) less than six weeks old: lipid values (fasting total cholest
glucose, HbA1c, renal values (serum creatinine, microalbustix albumin, microalbusti
inhibitors, glinides, glitazones, DPP-4 inhibitors) 7) ACE inhibitors, ARBs, renin inhibi
before baseline visit and since baseline or last FU, respectively.generated for the overall patient population. Depending
on the variable(s) of interest, additional selection criteria
for patients (e.g. subgroup analyses) considered in spe-
cific analyses may be used, if considered useful during
the statistical analysis. Details on the selection criteria
used will be given in the SAP and in the statistical section
of the report. The statistical analysis will be performed
using SAS (release 9.2 or higher; Cary, NC, USA).
Discussion
There are a number of epidemiological studies, which
documented (among other aspects) the treatment of
type-2 diabetes in Germany. Table 2 gives an overview
of those studies closely related to the objectives of
DIALOGUE. These include DUTY [34], DIG [35-37] and
DiaRegis [2,38-40]. DUTY (2001–2003) was among the
first [34] to prospectively document the effect of a tailored
intervention on blood glucose and CV risk factor target
achievement. They demonstrated that too many patients
suffering from diabetes mellitus do not receive consistent
therapy for cardiovascular risk factors according to









t status, care level 2) weight, height, waist circumference, smoking, alcohol
tion, previous PCI, previous CABG, previous stroke, heart failure (NYHA)
pathy, non- proliferative/proliferative retinopathy, diabetic macular edema,
erol, fasting LDL, fasting HDL, triglycerides), fasting and post-prandial blood
x creatinine), liver parameters. 6) metformin, sufonylureas, glucosidase
tors, beta blockers, calcium channel blockers, diuretics, other) 8) 12 months
Table 2 Comparison of DIALOGUE with other existing registries
DIALOGUE DiaRegis DIG DUTY
Reference [2,38-40] [35-37] [34]
No. of physicians Up to 700 313 238 n.a.
No. of patients Up to 10,000 3,810 4,020 59,035
Recruitment Starting 06/2012 06/2009–03/2010 2002-2004 2001-2003
Follow-up 2-4 years 2 years 4 years 9 months





Yes (2%) Yes (10%) None None
Proportion T2D 100% 100% 100% 100%
Patients Co-morbid disease of diabetes and
hypertension








n.a. 65.9 Mean 61.8 ± 8.1 64.4 ± 11.7
Female (%) n.a. 46.7 46.8 50.9
BMI (median) n.a. 30.0 Mean 30.7 ± 5.2 Mean 28.7 ± 4.8
Focus Target achievement with respect






Effect of tailored intervention
on target achievement
Legend. n.a., not available.
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and had a four year follow-up and meant to document
guideline-oriented treatment across Germany. A major
secondary focus was to investigate the metabolic syn-
drome in Germany. DiaRegis [2,38-40] is a prospective
registry focussing on the role of hypoglycaemia on sub-
sequent vascular events. Throughout the follow-up a
steady increase in the incidence of vascular events was
documented, suggesting an association between hyper-
glycaemia and vascular events [41].
Most of these studies however either had a detailed
look on the prevalence of type-2 diabetes in primary care
practice (HYDRA and DETECT), the co-morbidity bur-
den (DETECT), the costs (CODE-2, CoDiM and ROSSO),
or on self-monitoring of blood glucose (ROSSO). Some
were also retrospective in design (CODE-2, CoDiM and
ROSSO). Similar to DIALOGUE the effect of a tailored
intervention on target achievement was investigated in
DUTY and DIG. The added value of DIALOGUE is, that
it will enrol almost 10,000 patients exclusively with the
co-morbid disease constellation diabetes and hyperten-
sion and the effect of two matching treatment approaches
on target goal achievement as to the more recent guide-
lines which suggest more individualized treatment targets
[33,42,43] based on increasing calls for a move toward
more patient-centred care [44,45].
Conclusions
DIALOGUE is the first registry that focuses at the evalu-
ation of T2D patients who also suffer from hypertension,addressing both achievement of glycaemic and anti-
hypertensive goals considering the individualized treat-
ment targets as recommended by recent guidelines. As
the combination of both diseases is a major factor in the
development of vascular complications, data obtained will
help to explain the gap between the inadequate glycaemic
and blood pressure control in the “real world setting” des-
pite the demonstrated efficacy and safety of anti-diabetic
and anti-hypertensive drugs in clinical trials.
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